@abangelabs.bsky.socialFourteen social-science approaches expand how HTA teams assess uncertainty and support implementation. https://www.mattheneus.com/editorial/social-science-uncertainty-method-selection-hta-policy-implementation-2026-10-02 #HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialSweden’s Jaypirca decision shows how unanchored MAIC and Bayesian network analysis can shape CLL access. #HTA #MAIC #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/tlv-jaypirca-pirtobrutinib-cll-unanchored-maic-bayesian-nma-cost-comparison-2026-09-30
@abangelabs.bsky.socialG-BA divided belantamab mafodotin into four myeloma patient groups and found added benefit in only one. #HTA #EvidenceSynthesis https://www.mattheneus.com/editorial/g-ba-belantamab-mafodotin-bortezomib-dexamethasone-dreamm7-resolution-2026-10-01
@abangelabs.bsky.socialOnly complete pathologic response cleared the individual-level surrogacy threshold in pancreatic cancer.
#HTA #EvidenceSynthesis
@abangelabs.bsky.socialA Brazilian expert panel split equity and acceptability into two separate evidence jobs.
https://www.mattheneus.com/editorial/brazil-hta-equity-acceptability-delphi-consensus-evidence-strategy-2026-09-30
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.social96 trials in one network, and only one digital sleep therapy clears the clinical threshold.
https://www.mattheneus.com/editorial/pubmed-digital-therapeutics-sleep-quality-network-meta-analysis-mcid-2026-09-30
#HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialRegulators and payers endorsed hierarchical composite endpoints in infectious disease trials, then split on tiebreakers. https://www.mattheneus.com/editorial/hierarchical-composite-endpoint-infectious-disease-regulatory-reimbursement-acceptability-2026-09-30 #HTA #EvidenceSynthesis
@crd-uoy.bsky.socialWant to learn how systematic reviews are done? 📚
Our online Introduction to Systematic Reviews course runs 9-20 Nov, led by CRD experts at Uni of York. Open to any role or discipline.
@abangelabs.bsky.socialGermany has cleared secondary use of cervical screening programme data to study why participation lags. Registry access as evidence infrastructure. https://www.mattheneus.com/editorial/g-ba-cervical-screening-secondary-data-use-approval-participation-2026-09-24 #HTA #RWE #EvidenceSynthesis
@abangelabs.bsky.socialRozanolixizumab now sits beside efgartigimod and immunoglobulin in myasthenia gravis, but anchored and unanchored adjustments differ in weight. https://www.mattheneus.com/editorial/pubmed-rozanolixizumab-fcrn-anchored-unanchored-population-adjustment-evidence-2026-09-29 #HTA #MAIC #EvidenceSynthesis
@scienceeurope.orgDuring #ESDW2026, we’re highlighting how research supports #sustainabledevelopment by ensuring the right evidence reaches decision-makers when they need it.
Our new report explores how rapid and living #evidencesynthesis can help bridge the gap.
@trialschangelives.bsky.socialJust published! INSPECT-SR. New tool for systematic reviewers for assessing the trustworthiness of randomised trials
www.bmj.com/content/394/...
@abangelabs.bsky.socialClone every patient into every strategy, then censor and weight: it is how treatment-timing comparisons keep index dates aligned and avoid immortal time. https://www.mattheneus.com/editorial/clone-censor-weight-treatment-timing-index-date-alignment-2026-09-28 #HTA #RWE #EvidenceSynthesis
@abangelabs.bsky.socialFibromyalgia trials measure pain with too many different instruments to compare, so which one should a protocol pre-specify? https://www.mattheneus.com/editorial/fibromyalgia-patient-reported-instrument-fragmentation-trial-comparability-2026-09-28 #HTA #EvidenceSynthesis #RWE
@abangelabs.bsky.socialSeventy-one trials, and activity interventions for older adults still have no stable quality-of-life ranking. https://www.mattheneus.com/editorial/pubmed-older-adults-activity-interventions-quality-of-life-bayesian-network-meta-analysis-2026-09-28 #HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialWhich registries can support evidence planning in non-muscle-invasive bladder cancer? A German review found two active studies. #HTA #RWE #EvidenceSynthesis https://www.mattheneus.com/editorial/iqwig-non-muscle-invasive-bladder-cancer-registry-search-2026-09-28
@abangelabs.bsky.socialUtility mapping can fail exactly where accuracy matters most for survivors in poor health. https://www.mattheneus.com/editorial/gynaecological-cancer-eq5d-mapping-low-utility-accuracy-2026-09-27 #HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialHealth-state mapping can be least accurate where decisions are most sensitive: survivors in the poorest health. https://www.mattheneus.com/editorial/gynaecological-cancer-eq5d-mapping-low-utility-accuracy-2026-09-27 #HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialZero eligible trials can still guide policy. Germany’s colorectal screening review maps a critical evidence gap. https://www.mattheneus.com/editorial/iqwig-colorectal-screening-age-interval-zero-trial-model-2026-04-15 #HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialCan bedtime dosing improve hypertension outcomes? A five-trial network meta-analysis offers an exploratory ranking. https://www.mattheneus.com/editorial/pubmed-antihypertensive-chronotherapy-star-network-ranking-2026-09-25 #HTA #NMA #EvidenceSynthesis #HealthEconomics